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Abstract 
In recent years, new drugs have increasingly been developed globally, and the 
number of new drugs that are approved simultaneously in Japan, the US, and Europe 
has been increasing; it has brought about the situation that less safety information on 
Japanese patients than before is available for use at the time of the Japanese market 
launch. Postmarketing safety measures for new drugs in Japan are for this reason 
becoming more important. Against this background, the risk management plan (RMP) 
system was introduced in Japan in 2013, to enhance the planning and implementation of 
pharmacovigilance and risk-minimization activities. This system often requires 
additional pharmacovigilance activities. 
This study was conducted to discuss effective implementation of pharmacovigilance 
activities aimed at further improving the safety measures implemented for new drugs in 
Japan. We investigated 49 new active substances approved in 2013 and 2014 in Europe, 
where the RMP system was introduced earlier than in Japan, for their safety concerns 
and pharmacovigilance activities of RMPs as well as the main reasons why these 
pharmacovigilance activities were selected. We also comparatively investigated the 
safety concerns and pharmacovigilance activities of 20 products that have recently been 
approved both in Japan and Europe. In Europe, various types of additional 
pharmacovigilance activities were planned, and whether or not they are implemented 
depended on the product characteristics and their related safety concerns. The types of 
safety concerns for which non-clinical studies were most frequently conducted were 
teratogenicity and drug interactions, those for which clinical trials were conducted were 
long term use, and those for which non-interventional studies were conducted were 
medication errors and off-label use. Safety concerns for which additional 
pharmacovigilance activities were conducted accounted for around 40% of all safety 
concerns, and for around 30% of all known (identified) safety concerns. In Japan, in 
contrast, they accounted for 80% of all safety concerns, and 90% of known safety 
concerns. The only additional pharmacovigilance activities in Japan were postmarketing 
surveillance studies and postmarketing clinical studies.  
In light of these findings, we believe that it would be possible to collect safety 
information from a wide range of perspectives in Japan as well by researching the safety 
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concerns that have been identified for an individual drug product through (1) identifying 
safety concerns by predicting how the drug product will be used in the clinical setting, 
irrespective of the risks of “specific adverse events,” (2) evaluating whether or not 
additional pharmacovigilance activities are really needed, and not conducting additional 
pharmacovigilance activities for safety concerns for which additional information can 
be collected through only routine pharmacovigilance activities, and (3) positioning and 
conducting nonclinical studies and/or various types of observational studies as 
additional pharmacovigilance activities. Furthermore, because medical institutions and 
companies do not have unlimited resources, we believe that the focus of collecting 
information by conducting additional pharmacovigilance activities needs to be on the 
detection of unknown risks and the specific conditions of use rather than on collecting 
additional information about known adverse events. 
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1. Introduction 
New drugs used to be approved in Japan after they had already been approved in the 
West. This was because new drugs that had been discovered in the West were developed 
first in the West, with clinical studies being initiated and the new drug application being 
submitted in Japan later1, 2). On the other hand, one side benefit of this was that when a 
drug was launched in Japan, safety information that had already been collected in the 
West was available to provide more complete information, such as precautions, in the 
package insert. It was shown, in fact, that fewer safety measures were implemented 
postmarketing in Japan for new drugs whose market launches trailed those in the West3). 
In recent years, however, new drugs have increasingly been developed globally, and the 
number of new drugs that are approved simultaneously in Japan, the US, and Europe 
has therefore been increasing, which has brought about the situation that less safety 
information than before is available for use at the time of the Japanese market launch. 
Postmarketing safety measures for new drugs in Japan are for this reason becoming 
more important. 
For a drug product to be used properly and safely in clinical practice, companies and 
regulatory authorities must provide medical professionals and patients with enough 
information about the efficacy and safety of the drug product. However, at the time of 
the market launch of a drug product, only a limited amount of safety information is 
available. This is because the clinical studies conducted to file a marketing approval 
application (1) include only a small number of patients compared to the size of the 
target population; (2) restrict the age, sex, and/or ethnicities of the patients who are 
enrolled in the clinical studies, the concomitant therapies and drugs that can be used, 
and also the way in which the drug product can be used; and (3) use short durations of 
exposure and follow-up4). A considerable amount of new safety information is generated 
postmarketing when a drug product is used in a large number of patients by a large 
number of physicians in the clinical setting. Therefore, both the company and the 
regulatory authorities must collect safety and efficacy information postmarketing as 
well, and assess the risk-benefit balance and implement any required measures based on 
this new information, and also provide medical professionals in the clinical setting with 
this information. 
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As a tool for accomplishing this objective, the risk management plan (RMP) system 
was introduced in Europe in 2005 and in Japan in 2013, and RMPs are now mandatory 
for all newly approved drugs. A unique RMP is prepared for each drug product.  
Companies must submit a draft RMP when filing for approval of a drug product, and, 
prior to the market launch, the RMP is finalized through discussions with the regulatory 
authorities. After the market launch, companies must revise the RMP, if necessary, 
based on assessments of safety information obtained, and continue to clarify and control 
important risks.  
RMPs have three stages: (1) characterization of the safety profile of the drug product, 
(2) planning of pharmacovigilance activities to increase knowledge about the safety 
profile of the product, and (3) planning of risk-minimization activities and assessment 
of the effectiveness of these activities4). In stage (1), ‘Characterization of the safety 
profile’, all safety concerns are described in detail and classified as ‘important identified 
risks,’ ‘important potential risks,’ or ‘missing information’4). Identified risks are risks 
for which a causal relationship to the drug product has been adequately demonstrated in 
nonclinical studies and that have been confirmed in clinical studies as well, potential 
risks are risks for which findings have been obtained in nonclinical studies suggesting 
that the events could be the risks of the drug product but which have not been confirmed 
in clinical studies, and missing information is information that is needed in the clinical 
setting but that needs to be obtained from patient populations that were excluded from 
the clinical studies5). Therefore, risks that are classified as potential risks at market 
launch are sometimes reclassified as identified risks depending on the safety 
information that is subsequently obtained. 
Two types of pharmacovigilance activities are planned and conducted to address 
these safety concerns: routine activities (such as spontaneous reporting of adverse 
events) and additional activities (such as interventional/observational studies). Routine 
pharmacovigilance activities are conducted for all safety concerns. The drug product 
characteristics and the nature of the safety concerns will dictate whether or not 
additional pharmacovigilance activities are conducted (Figure 1)4, 5). In Europe, 
additional pharmacovigilance activities contain non-clinical studies, clinical trials, or 
non-interventional studies (observational studies), in accordance with the Guideline on 
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Good Pharmacovigilance Practices4). In Japan, additional pharmacovigilance activities 
have, since before the introduction of the RMP system, been classified as 
“postmarketing surveillance studies” or “postmarketing clinical studies,” in accordance 
with the Japanese GPSP Ministerial Ordinance. While postmarketing surveillance 
studies are conducted for almost all new drugs, postmarketing clinical studies are rarely 
conducted. 
 
Figure 1: Flow diagram of safety concerns and pharmacovigilance activities in the Risk 
Management Plan 
 
The research that has been conducted to date7-11) has identified several problems with 
the postmarketing surveillance studies that were being conducted in Japan prior to the 
introduction of the RMP system, such as the complexity of the case report forms and the 
large number of parameters that needed to be filled out, even though the people 
primarily responsible for conducting these investigations at medical institutions were 
physicians who were already extremely busy. These postmarketing surveillance studies 
therefore placed a considerable burden on these physicians. Another problem was that 
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the postmarketing surveillance studies did not have clear objectives, and the information 
that was obtained was therefore not very helpful for formulating safety measures. In 
other words, even though a tremendous amount of time and expense was being spent by 
physicians and others at medical institutions completing the case report forms and by 
companies collecting the case report forms and tabulating and assessing the information 
obtained, this information was not being utilized. Furthermore, research on the RMPs 
that have been prepared since the RMP system was introduced12, 13) has shown that the 
additional pharmacovigilance activities still depend to a large extent on traditional 
postmarketing surveillance studies, and that the aforementioned problems have 
therefore not yet been resolved. 
In Japan, RMPs must identify various safety concerns of a new drug, and the 
information that is needed to assess these safety concerns must be collected and 
analyzed in a timely fashion. However, no research has been conducted into what kinds 
of pharmacovigilance activities should be formulated for what specific types of safety 
concerns. In this study, therefore, we investigated the safety concerns and 
pharmacovigilance activities of RMPs in Europe, where the RMP system was 
introduced earlier than in Japan, as well as the main reasons why these 
pharmacovigilance activities were selected, and also comparatively investigated the 
safety concerns and pharmacovigilance activities of products that have recently been 
approved both in Japan and Europe. Based on the results obtained, we discuss the 
effective implementation of pharmacovigilance activities aimed at further improving the 
safety measures that are implemented for new drugs in Japan. 
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2. Part I:  Characterization of the Recent Postmarketing Safety Measures in 
Europe Focusing on Additional Pharmacovigilance Activities 
 
2.1. Part I: Objectives 
In 2005, the European Medicines Agency introduced a risk-management system as a 
means of planning and implementing pharmacovigilance and risk-minimization 
activities for new drugs in the EU. This has proven to be an effective means of gaining 
information on safety and of minimizing risks for new drugs postmarketing14, 15). Since 
the issuance of the pharmacovigilance legislation in 2012, pharmacovigilance activities 
appropriate to the risks have been proactively implemented across the entire life-cycle 
of drug products16). 
A unique risk-management plan (RMP) is created for each drug product. Companies 
submit an RMP when filing for approval of a drug product, and the submitted RMP is 
assessed by the Pharmacovigilance Risk Assessment Committee (PRAC) then approved 
by the Committee for Medicinal Products for Human Use (CHMP). RMPs are now 
delivered for all new centrally authorized products17). Since March 2014, the EMA has 
published summaries of the RMPs for all products. 
To plan pharmacovigilance activities from which companies and regulatory 
authorities can obtain practical information to enable the evaluation of the benefit–risk 
balance of drug products, it is important to understand what pharmacovigilance 
activities have been implemented for comparable drugs or safety concerns as well as the 
product characteristics and the pathology of and treatments for the targeted disease. 
Research has been conducted on the contents of additional risk-minimization activities 
at approval18), changes in safety concerns after the acquisition of new information14), 
and additional post-approval pharmacovigilance activities implemented19). However, no 
research has comprehensively investigated the additional pharmacovigilance activities 
for new drug products and associations between these activities and safety concerns 
since the pharmacovigilance legislation took effect. 
In Part I, we investigated the characteristics of the safety concerns for products 
approved since the pharmacovigilance legislation took effect in the EU and associations 
between these safety concerns and pharmacovigilance activities, with the aim of 
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enhancing the planning and implementation of future pharmacovigilance activities in 
Japan.  
 
2.2. Part I: Methods 
2.2.1. Data Source and Data Extraction 
We studied 49 of the 67 new active substances approved between January 2013 and 
December 2014 in the EU for which the European Public Assessment Reports (EPARs) 
had been posted on the EMA website20) (we excluded one withdrawn product, one 
suspended product, eight combination drug products, and eight products for which 
detailed pharmacovigilance plan information was not included in the EPAR). 
For each of the 49 drug products, we extracted the‘Summary of safety concerns’ and 
‘Pharmacovigilance plans’ subsections from the RMP section of the EPAR posted as an 
initial marketing authorization document on the EMA website20). On 1 January 2016, 
we also downloaded the background information for each of the drug products (active 
substance, anatomical therapeutic chemical [ATC] code, status, authorization date, and 
approval details) from the same website and summarized the product characteristic 
information (product type, therapeutic group, approval details, and the region of first 
approval worldwide). We confirmed which parts of the pharmacovigilance plans 
constituted additional pharmacovigilance activities based on the information available 
in the EPARs and on the clinicaltrials.gov21) and European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP) websites22). 
 
2.2.2. Data Classification 
2.2.2.1. Safety Concerns 
Safety concerns are classified in the RMP as important identified risks, important 
potential risks, or missing information. We divided all safety concerns into either 
‘specific adverse event’ (SpAE) or ‘context of use.’ We further categorized SpAEs 
according to Medical Dictionary for Regulatory Activities (MedDRA) version 18.1 
system organ classes (SOCs) and categorized the contexts of use into the following 
categories: use in specific age groups, use during pregnancy/lactation, use in patients 
with specific comorbidities, use with concomitant medications (including interactions), 
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abuse/misuse/medication errors, long-term use, use in unstudied ethnicities, and 
off-label use. Some safety concerns were classified as both SpAE and context of use. 
 
2.2.2.2. Additional Pharmacovigilance Activities 
The ‘pharmacovigilance plans’ subsections listed the study/activity type, title and 
category, objectives, safety concerns addressed, status, and date for submission of 
interim or final reports for the additional pharmacovigilance activities. We extracted this 
information and linked the safety concerns with the additional pharmacovigilance 
activities based on the information pertaining to the ‘safety concerns addressed.’ 
We categorized all additional pharmacovigilance activities as non-clinical studies 
(e.g., pharmacology studies, general toxicity studies, toxicokinetic and nonclinical 
pharmacokinetic studies, reproduction toxicity studies, genotoxicity studies), clinical 
trials (e.g., human interventional studies such as human pharmacology studies, 
therapeutic confirmatory studies, and clinical studies in special populations), or 
non-interventional (observational) studies (e.g., cohort studies, drug-utilization studies). 
When we could not classify the type of additional pharmacovigilance activity based 
solely on information from the EPAR, we consulted the clinicaltrials.gov21) and 
ENCePP websites22). In addition, we further categorized the objectives of clinical trials 
as either efficacy and safety, safety, or pharmacokinetics and the status of each 
pharmacovigilance activity as either planned/being planned, ongoing, or completed. 
We analyzed associations between the product characteristics and safety concerns, 
between the product characteristics and additional pharmacovigilance activities, and 
between safety concerns and additional pharmacovigilance activities. 
 
2.3. Part I: Results 
2.3.1. Product Characteristics 
Table 2-1 shows the characteristics of the 49 drug products (see also the Appendix 1 
for more in-depth details) based on the product type. The most common therapeutic 
group was ‘L’ (antineoplastic and immunomodulating agents), comprising 12 
antineoplastic agents, three immunosuppressants, one endocrine therapy drug, and one 
immunostimulant. The next most common was ‘A’ (alimentary tract and metabolism  
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Table 2-1 Summary of product characteristics (Part I) 
 
 
 
 
 Small molecules 
(n = 34) 
Biologicals 
  (n = 15) 
Total 
(n = 49) 
Therapeutic group, n (%) L: Antineoplastic and immunomodulating agents 11 (22.4) 6 (12.2) 17 (34.7) 
 A: Alimentary tract and metabolism 4 (8.2) 5 (10.2)   9 (18.4) 
 J: Antiinfectives for systemic use 6 (12.2) 0   6 (12.2) 
 V: Various 5 (10.2) 0   5 (10.2) 
 N: Nervous system 3 (6.1) 0   3 (6.1) 
 Other groups 5 (10.2) 4 (8.2)   9 (18.4) 
Approval details, n (%) Orphan indication 9 (18.4) 4 (8.2) 13 (26.5) 
 Conditional approval 5 (10.2) 0   5 (10.2) 
 Exceptional Circumstance 1 (2.0) 0   1 (2.0) 
First approval worldwide, Europe 6 (12.2) 3 (6.1)   9 (18.4) 
n (%) United States 22 (44.9) 10 (20.4) 32 (65.3) 
 Japan 3 (6.1) 1 (2.0)   4 (8.2)  
 Rest of the world 3 (6.1) 1 (2.0)   4 (8.2) 
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drugs), comprising seven diabetes drugs, one constipation drug, and one ‘other’ drug. In 
total, 13 of the drugs had orphan indications and five had conditional approval. The 
most common region of first approval was the USA. 
 
2.3.2. Safety Concerns 
In total, 813 safety concerns were recorded for the 49 products studied, with a median 
of 17 per product (interquartile range [IQR] 13.0–21.0). There was no difference in 
median number of safety concerns when broken down by product type: small-molecule 
drugs 17.0 (IQR 13.0–20.8); biologicals 17.0 (IQR 13.0–20.5). When based on approval 
status, the median number was 19.0 (IQR 17.0–22.0) for orphan drugs, 17.0 (IQR 11.8–
20.0) for non-orphan drugs, 20.0 (IQR 19.0–22.0) for drugs with conditional approval, 
and 17.0 (IQR 11.8–20.3) for those without conditional approval. Figure 2-1 shows the 
number of safety concerns per product based on the key therapeutic groups. Drugs 
classified in therapeutic groups L and N had the most safety concerns. 
 
Figure 2-1: Number of safety concerns per product by therapeutic groups 
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When safety concerns were categorized by type of concern, we found 206 important 
identified risks, 287 important potential risks, and 320 categorized as missing 
information. Of the 813 concerns, 426 (52.4%) were SpAEs and 409 (50.3%) were 
context of use concerns. (Percentages may not add to 100 because some concerns were 
classified as both SpAE and context of use and 11 safety concerns were not included in 
either category; Table 2-2.) Almost all identified risks were SpAEs. Two-thirds of the 
potential risks were SpAEs and one-third were classified as context of use. In contrast, 
most of the missing information was classified as context of use (Fig. 2-2). 
 
2.3.3. Additional Pharmacovigilance Activities 
In total, 300 additional pharmacovigilance activities were planned to address specific 
safety concerns, including 143 clinical trials (47.7%), 73 non-interventional studies 
(24.3%), and 72 non-clinical studies (24.0%). Based on product type, the median 
number of additional pharmacovigilance activities was 5.5 (IQR 3.0–9.0) for 
small-molecule drugs and 3.0 (IQR 2.0–6.0) for biologicals. Based on approval status, 
the median number of additional pharmacovigilance activities was 7.0 (IQR 3.0–11.0) 
for orphan drugs, 4.5 (IQR 2.0–7.0) for non-orphan drugs, 15.0 (IQR 11.0–15.0) for 
drugs with conditional approval, and 4.0 (IQR 2.0–7.0) for drugs without conditional 
approval. 
Table 2-3 shows the associations between the type and status of additional 
pharmacovigilance activities. The proportion of additional pharmacovigilance activities 
that were already or being planned was high for non-interventional studies, and the 
proportion of ongoing activities was high for clinical trials. The objectives of the 92 
clinical trials for which the status was ‘ongoing’ were as follows: efficacy and safety 52 
(56.5%); safety 22 (23.9%); pharmacokinetics 16 (17.4%); unknown 2 (2.2%). 
Meanwhile, the objectives of the 47 clinical trials for which the status was 
‘planned/planning’ were as follows: pharmacokinetics 21 (44.7%); efficacy and safety 
15 (31.9%); safety 9 (19.1%); and unknown 2 (4.3%). 
The median number of additional pharmacovigilance activities per drug product was 
5.0 (IQR 3.0–8.0), with at least one additional pharmacovigilance activity conducted for 
each of the 49 products: non-clinical studies were conducted for 21 products, clinical 
trials for 40 products, and non-interventional studies for 38 products. 
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We studied associations between the type of study and the therapeutic group. 
Therapeutic groups with high proportions of non-clinical studies were groups J (21 of 
54 [38.9%]) and L (38 of 131 [29.0%]); those with high proportions of clinical trials 
were groups N (8 of 15 [53.3%]) and L (69 of 131 [52.7%]). Clinical trials were being 
conducted as additional pharmacovigilance activities for 57 of the antineoplastic agents 
in therapeutic group L. We also investigated associations between the additional 
pharmacovigilance activity status and therapeutic group. Drugs in therapeutic group L 
had a high proportion of ongoing additional pharmacovigilance activities (68 of 131 
[51.9%]). 
 
 
 
Figure 2-2: Safety concerns by types and how these are intended to be addressed 
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Table 2-2 Characteristics of safety concerns listed in the Risk Management Plan 
 
1) Specific Adverse events (SpAEs) categorized according to Medical Dictionary for 
Regulatory Activities (MedDRA) 
2) For 11 safety concerns, a combination of one SpAE and one or two contexts of use 
was specified (e.g., neoplasms + interactions). For 11 safety concerns (pharmacokinetic 
data), neither was specified.  For 20 safety concerns, a combination of two or three 
contexts (e.g., patients with hepatic impairments + pregnancy) was specified.   
  
 
n (%) 
Safety concerns by type   
  Important Identified Risks 206   (25.3) 
Important Potential Risks   287   (35.3) 
Missing Information 320   (39.4) 
   
Nature of safety concerns by specific adverse event1, 2), n (%) 426   (52.4) 
Gastrointestinal disorders 34    ( 4.2) 
Immune system disorders 33    ( 4.1) 
Vascular disorders  30    ( 3.7) 
Investigations 29    ( 3.6) 
Blood and lymphatic system disorders 27    ( 3.3) 
Neoplasms benign, malignant and unspecified (incl. cysts and polyps) 25    ( 3.1) 
Infections and infestations 24    ( 3.0) 
Injury, poisoning and procedural complications 24    ( 3.0) 
Others 200   (24.6) 
Nature of safety concerns by context of use2), n (%) 409   (50.3) 
Patients with comorbidities 145   (17.8) 
Specific age groups 64    ( 7.9) 
Concomitant medication/ interaction 63    ( 7.7) 
Pregnancy, lactation  47    ( 5.8) 
Off-label use 30    ( 3.7) 
Long-term use 20    ( 2.5) 
Abuse, misuse, medication error 19    ( 2.3) 
Unstudied ethnicity 10    ( 1.2) 
Others 11    ( 1.4) 
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Table 2-3 Type and Status of additional pharmacovigilance activities (Part I) [n (%)] 
 
2.3.4. Associations between Safety Concerns and Additional Pharmacovigilance 
Activities 
In total, 300 specific additional pharmacovigilance activities were being implemented 
for 418 of the safety concerns. Multiple additional activities were being implemented 
for some safety concerns, and, in some instances, a single additional pharmacovigilance 
activity was being implemented for multiple safety concerns. The maximum number of 
additional activities per safety concern was 16 (minimum 0, median 2.0, IQR 0–2.0), 
whereas the maximum number of safety concerns per additional pharmacovigilance 
activity was 24 (minimum 1, median 1.0, IQR 1.0–3.0). 
 
2.3.4.1. Frequency of Additional Pharmacovigilance Activities Based on the Type of 
Safety Concerns 
When we investigated the proportions of the type of safety concerns for which 
additional pharmacovigilance activities were being conducted, we found that the 
proportion was highest for potential risks (n = 165 [57.5%]), followed by missing 
information (n = 173 [54.1%]) and identified risks (n = 80 [38.8%]). Figure 2-2 shows 
whether or not additional pharmacovigilance activities were conducted for each type of 
concern, with the concerns further classified into SpAEs or context of use. The most 
common SpAEs for which additional pharmacovigilance activities were being 
conducted were neoplasms (16 of 25 [64.0%]), blood and lymphatic system disorders 
(17 of 27 [63.0%]), infections and infestations (15 of 24 [62.5%]), investigations (18 of 
 Planned 
/Planning 
Ongoing Completed Unknown Total 
Clinical trial  47 (32.9)  92 (64.3)   3 (2.1)   1 (0.7) 143 
Non-interventional 
study 
 68 (93.2)    3 (4.1)   0    2 (2.7) 73 
Non-clinical study  38 (52.8)  29 (40.3)   4 (5.6)   1 (1.4) 72 
Unknown   3 (25.0)   5 (41.7)   2 (16.7)   2 (16.7) 12 
Total 156 (52.0) 129 (43.0)   9 (3.0)   6 (2.0) 300 
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29 [62.1%]), and immune system disorders (17 of 33 [51.5%]). The most common 
context of use concerns for which additional pharmacovigilance activities were being 
conducted were long-term use (16 of 20 [80.0%]), use with concomitant medications 
(including interactions) (42 of 63 [66.7%]), abuse/misuse/medication errors (12 of 19 
[63.2%]), use in specific age groups (38 of 64 [59.4%]), and off-label use (17 of 30 
[56.7%]).  
 
2.3.4.2. Associations between Safety Concerns and Additional Pharmacovigilance 
Activity Study Type 
The median number of safety concerns associated with one study was 1.0 (IQR 1.0–
1.0) for non-clinical studies, 1.0 (IQR 1.0–3.8) for clinical trials, and 2.5 (IQR 1.0–7.0) 
for non-interventional studies.  
Figure 2-3 shows associations between the types of safety concerns and the type of 
additional pharmacovigilance activity. The type of safety concern for which non-clinical 
studies were most frequently conducted were injury, poisoning, and procedural 
complications (n = 9 [39.1%]) and use with concomitant medications, including 
interactions (n = 42 [38.2%]). The most common type of safety concerns for which 
clinical trials were conducted were blood and lymphatic system disorders (n = 57 
[83.8%]), long-term use (n = 35 [68.6%]), and use in unstudied ethnicities (n = 7 
[63.6%]). The most common types of safety concerns for which non-interventional 
studies were conducted were abuse/misuse/medication errors (n = 15 [83.3%]), off-label 
use (n = 15 [57.7%]), and infections and infestations (n = 20 [57.1%]). 
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Figure 2-3: Associations between different types of safety concerns and additional pharmacovigilance activities 
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2.4. Part I: Discussion 
The Guideline on Good Pharmacovigilance Practices, module V: Risk Management 
Systems, issued in 20124), states that additional pharmacovigilance activities may or 
may not be conducted depending on the characteristics of the drug product and the 
extent to which the safety concerns have been clarified. The present study supports this 
idea. It was also clear that the additional pharmacovigilance activity study type and/or 
status differed depending on the therapeutic group and/or the type of safety concerns for 
the product.  
Identified risks were somewhat less common than either potential risks or missing 
information, and SpAE concerns were more common than context of use concerns. 
These results are similar to those obtained in a study of 48 new drug products that were 
approved between November 2005 and December 200914). 
The number of safety concerns per product was largest for products in therapeutic 
groups L and N. The number of additional pharmacovigilance activities per product was 
largest for products in therapeutic groups J, N, and L. These results suggest the 
therapeutic group affects the safety concerns and pharmacovigilance activities. The 
median number of safety concerns per product was the same for small-molecule drugs 
and biologicals. Per product, more additional pharmacovigilance activities were 
undertaken for small-molecule drugs. Therefore, we cannot say definitively that a 
product will necessitate more additional pharmacovigilance activities solely because it 
is a biological. Products that were orphan drugs or had conditional approval had more 
safety concerns and additional pharmacovigilance activities than those that were not 
orphan drugs or without conditional approval. This may reflect that orphan drugs and 
drugs with conditional approval were approved with relatively limited safety 
information. 
While most identified risks and potential risks were SpAEs, the majority of the 
missing information related to context of use concerns. In addition, the proportion of 
safety concerns for which only routine pharmacovigilance activities were conducted 
was highest for identified risks. Therefore, it was clear that additional 
pharmacovigilance activities were conducted less frequently for risks that had already 
been identified at the time of approval. 
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Clinical trials were the most common additional pharmacovigilance activities. In 
particular, more than 60% of the additional pharmacovigilance activities conducted for 
long-term use were clinical trials. Given these, the fact that a high proportion of 
ongoing activities were clinical trials suggests that a fairly large number of clinical trials 
conducted to obtain marketing approval were continued post-approval to collect 
information on safety in long-term use. Thus, it appears that clinical trials are planned 
right from the development stage, taking into account pharmacovigilance activities that 
will be conducted post-approval. Conversely, the status for most of the 
non-interventional studies was ‘planned/being planned,’ reflecting the nature of this 
type of study. 
The additional pharmacovigilance activities that were conducted for the majority of 
abuse/misuse/medication errors and for close to 60% of off-label use were 
non-interventional studies. These are safety concerns that are encountered only 
post-approval, which means non-interventional studies appear to be suited to the 
characteristics of these safety concerns. Close to 40% of the additional 
pharmacovigilance activities conducted for injury, poisoning, and procedural 
complications were non-clinical studies. This was a far higher proportion than that for 
other risks. Furthermore, close to 40% of the additional pharmacovigilance activities 
conducted for use with concomitant medications (including interactions) were 
non-clinical studies. These activities also appeared to be well suited to the 
characteristics of these safety concerns. 
These results suggest that whether additional pharmacovigilance activities are 
conducted or not depends on the characteristics of the therapeutic group and the level of 
safety concerns for the particular drug. Furthermore, these factors also dictate the type 
of study when additional pharmacovigilance activities are conducted. Additional 
pharmacovigilance activities are conducted more frequently for safety concerns for 
which sufficient clinical data have not been obtained prior to approval, such as potential 
risks and missing information, than for identified risks. 
From the early stages of drug development, companies should consider what kind of 
safety information will be required in the postmarketing stage based on factors such as 
the product characteristics and anticipated safety concerns as well as the 
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pharmacovigilance activities already being conducted for comparable drugs or similar 
safety concerns. At the same time, pharmacovigilance activity plans should be updated 
based on accumulating postmarketing information. We believe the present study 
provides insight to enhance future postmarketing pharmacovigilance activities. 
The limitations of our study include that the data were extracted from the EPARs at 
the time of approval and thus may differ somewhat from the actual RMPs. Furthermore, 
it may be possible that a clinical trial conducted to address one primary safety concern 
may also study other safety concerns as a secondary objective; this might influence the 
number of safety concerns addressed in any particular clinical trial. 
 
2.5. Part I: Conclusions 
The necessity for and types of additional pharmacovigilance activities depend on the 
characteristics and the uncertainty about the safety concerns pertaining to the product. 
From the early stages of drug development, companies should consider the kind of 
safety information that will be required in the postmarketing stage and plan 
pharmacovigilance activities accordingly.  
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3. Part II: Comparative Analysis of Safety Concerns and Pharmacovigilance 
Activities in Japan and Europe 
 
3.1. Part II: Objectives 
Looking at the pharmacovigilance activities in Europe, where the RMP system was 
introduced earlier than in Japan, an analysis of the characteristics of the postmarketing 
safety concerns in Europe, as discussed in Part I, clearly shows that (1) the 
pharmacovigilance activities are related both to the characteristics and the safety 
concerns of the individual drug products and (2) additional pharmacovigilance activities 
are only conducted for around half of the safety concerns. Earlier studies of 
pharmacovigilance activities in Japan7-11) have identified several problems with the 
postmarketing surveillance studies that were being conducted in Japan prior to the 
introduction of the RMP system, such as the complexity of the case report forms and the 
large number of parameters that needed to be filled out, even though the people 
primarily responsible for conducting these investigations at medical institutions were 
physicians who were already extremely busy. These postmarketing surveillance studies 
therefore placed a considerable burden on these physicians. Another problem was that 
the postmarketing surveillance studies did not have clear objectives, and the information 
that was obtained was therefore not very helpful for formulating safety measures. 
Furthermore, research on the RMPs that have been prepared since the RMP system was 
introduced12, 13) has shown that the additional pharmacovigilance activities still depend 
to a large extent on traditional postmarketing surveillance studies. Therefore, the 
approach to pharmacovigilance that has been used in Japan since the time when there 
was a lag in the approval of new drugs in Japan compared to the West – in other words, 
since the time when it was possible to use the safety information that had already been 
collected in the West when the drug was launched in Japan – continues to be used 
despite the fact that now new drugs are approved in Japan at nearly the same time as in 
the West. 
However, although previous research has identified problems with the postmarketing 
surveillance studies themselves, no research has been conducted on what kinds of 
pharmacovigilance activities should be used for what kinds of safety concerns. 
Therefore, in Part II, we identify and categorize the numbers and types of safety 
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concerns, the numbers, types, and times of implementation of pharmacovigilance 
activities for each drug product that has recently been approved in both Japan and 
Europe, and comparatively analyze the associations between them and discuss methods 
for effectively implementing pharmacovigilance activities in order to realize a more 
complete set of new drug safety measures in Japan. 
 
3.2. Part II: Methods 
3.2.1. Data Sources and Data Extraction 
Of the 49 products discussed in Part I, 20 had been approved in Japan as well by 
August 2016 for the same indication, and the European data from Part I were therefore 
used without any modification. 
For these 20 products, we obtained the risk management plans listed on the PMDA 
web site23) and extracted the information on the safety concerns and also the 
pharmacovigilance activities that are being conducted for these safety concerns (titles of 
the activities, key/target numbers of subjects, key scheduled time points, status of 
conduction, planned date of report preparation). Early postmarketing phase vigilance 
activities were excluded from consideration because of the fact that, from a procedural 
standpoint, they are the same as routine pharmacovigilance activities. 
 
3.2.2. Data Classification 
3.2.2.1. Safety concerns 
We classified the safety concerns that were listed in the Japanese and European 
RMPs as identified risks, potential risks, or missing information. In addition, in order to 
compare the risks in Japan to those in Europe, we classified the safety concerns into the 
following 3 groups: those that were listed in the same risk category (identified 
risk/potential risk/missing information) in both the Japanese and the European RMP, 
those that were listed as risks, but in different risk categories, in the Japanese and 
European RMPs, and those that were listed in only one of the Japanese and European 
RMPs. We also classified identified risks as (a) risks that were listed as identified risks 
only in Japan, (b) risks that were listed as identified risks only in Europe, or (c) risks 
that were listed as identified risks in both Japan and Europe, and also investigated the 
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relationships between these risks and the times of approval of each product in both 
Japan and Europe. 
Separately, we classified all the safety concerns as “specific adverse events” (SpAEs) 
or “context of use concerns.” Context of use concerns were further classified into the 
following categories in accordance with the previous research14): use in specific age 
groups, use during pregnancy/lactation, use in patients with specific comorbidities, use 
with concomitant medications (including interactions), abuse/misuse/medication errors, 
long-term use in unstudied ethnicities, and off-label use. Some safety concerns were 
classified as both SpAEs and context of use concerns. 
 
3.2.2.2. Additional Pharmacovigilance Activities 
Additional pharmacovigilance activities in the European RMPs were classified as 
non-clinical studies (e.g., pharmacology studies, general toxicity studies, toxicokinetic 
and nonclinical pharmacokinetic studies, reproduction toxicity studies, genotoxicity 
studies), clinical trials (e.g., human interventional studies such as human pharmacology 
studies, therapeutic confirmatory studies, and clinical studies in special populations), or 
non-interventional (observational) studies (e.g., cohort studies, drug-utilization studies), 
in accordance with the EMA guidelines4). Additional pharmacovigilance activities in the 
Japanese RMPs were classified as postmarketing surveillance studies or postmarketing 
clinical studies, in accordance with the Japanese GPSP Ministerial Ordinance. The 
postmarketing surveillance studies were further classified by whether or not they were 
all-patient surveillance programs. For both Japan and Europe, the additional 
pharmacovigilance activities were also classified by status (planned/planning, ongoing, 
or completed). 
Then, for both Japan and Europe, the relationships between the drug characteristics 
and the safety concerns, the relationships between the drug characteristics and the 
additional pharmacovigilance activities, and the relationships between the safety 
concerns and the additional pharmacovigilance activities were analyzed and these 
relationships in Japan were compared to those in Europe. 
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3.3. Part II: Results 
3.3.1. Product Characteristics 
Table 3-1 shows the product backgrounds. The therapeutic group with the most drug 
products was Group L (antineoplastic and immunomodulating drugs). There were 4 
products for which the region of first approval in the world was Japan and 1 product for 
which it was Europe; almost all of the other products were first approved in the United 
States. There were 5 products that were designated as orphan drugs in Europe, 7 
products designated in Japan, and 3 products designated in both regions (elosulfase alfa, 
ibrutinib, and pomalidomide). The difference between the international birth date and 
the date of approval was 136.0 days (interquartile range [IQR]: 60.3-233.8) in Europe 
and 327.0 days (IQR: 198.0-597.5) in Japan. 
 
3.3.2. Safety concerns 
The European and Japanese safety concerns for each drug product are shown in the 
appendix 2. The total number of safety concerns was 329 in Europe and 197 in Japan. 
The number of identified risks was 85 in Europe and 105 in Japan, the number of 
potential risks was 108 in Europe and 55 in Japan, and the number of missing 
information risks was 136 in Europe and 37 in Japan. Thus, although there was no 
major difference between Europe and Japan in the number of identified risks, the 
number of potential risks in Europe was around double as many as that in Japan, and the 
number of missing information risks in Europe was around 4 times more than that in 
Japan. There were 103 safety concerns that were listed as risks and also classified into 
the same category in both Europe and Japan, 192 that were listed as risks only in Europe, 
and 61 that were listed as risks only in Japan. 
Figure 3-1 shows the results of classifying the safety concerns as SpAEs or context of 
use concerns. Of the 329 concerns in Europe, 177 (53.8%) were SpAEs and 165 
(50.2%) were context of use. (Percentages may not add to 100 because some concerns 
were classified as both SpAE and context of use and 5 safety concerns were not 
included in either category.) By contrast, of 197concerns in Japan, 148 (75.1%) were 
SpAEs and 49 (24.9%) were context of use. In addition, the risks associated with 
context of use included risks that were listed as risks only in Europe (use in unstudied 
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ethnicities, off-label use). Figure 3-2 shows the results of a comparison of only the risks 
associated with context of use when these risks are excluded. 
The number of safety concerns per product was 11.0 (IQR: 5.8-14.0) in Japan and 
17.0 (IQR: 12.8-20.0) in Europe. When the relationship between the number of 
identified risks and the time of approval of each product was investigated, it was found 
that the disposition of the 94 identified risks for the 13 products that had been approved 
at least 180 days earlier in Europe than in Japan was as follows: 34 risks that were listed 
only in the Japanese RMP (36.2%), 29 risks that were listed only in the European RMP 
(30.9%), and 31 risks that were listed in both the European and the Japanese RMPs 
(33.0%). The disposition of the 16 identified risks for the 2 products that were approved 
at least 180 days earlier in Japan than in Europe was as follows: 12 risks that were listed 
as risks only in Japan (75.0%), 2 risks that were listed as risks only in Europe (12.5%), 
and 2 risks that were listed as risks in both Japan and Europe (12.5%). Of the 30 
identified risks for the 5 products for which the difference between Japan and Europe in 
the date of approval was less than 180 days, 9 (30.0%) were listed as risks only in Japan, 
4 (13.3%) were listed as risks only in Europe, and 17 (56.7%) were listed as risks both 
in Japan and in Europe. 
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Table 3-1: Summary of product characteristics (Part II)   
 
 
  
 
 
 
 Small molecules 
(n =16) 
Biologicals 
    (n = 4) 
Total 
(n = 20) 
Therapeutic group, n (%) L: Antineoplastic and immunomodulating agents  6 (30.0) 1 (5.0) 7 (35.0) 
 A: Alimentary tract and metabolism  3 (15.0) 3 (15.0) 6 (30.0) 
 J: Antiinfectives for systemic use  4 (20.0) 0 4 (20.0) 
 V: Various 1 (5.0) 0 1 (5.0) 
 N: Nervous system 0 0 0 
 Other groups  2 (10.0) 0 2 (10.0) 
Approval details, n (%) Orphan indication (Europe)  3 (15.0) 2 (10.0) 5 (25.0) 
 Conditional approval (Europe) 0 0 0 
 Exceptional Circumstance (Europe) 0 0 0 
 Orphan indication (Japan)  6 (30.0) 1 (5.0) 7 (35.0) 
 Priority review (Japan)  4 (20.0) 1 (5.0) 5 (25.0) 
First approval worldwide, Europe 1 (5.0) 0 1 (5.0) 
n (%) United States 10 (50.0) 3 (15.0) 13 (65.0) 
 Japan  3 (15.0) 1 (5.0) 4 (20.0) 
 Canada  2 (10.0) 0 2 (10.0) 
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Figure 3-1: Classification of the safety concerns as SpAEs or context of use 
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Figure 3-2: Classification of the safety concerns as context of use (excluded specific adverse events and risks only in Europe (use in unstudied 
ethnicities, off-label use) 
Japan 
Europe 65
27
25
10
25
7
19
2
9
2
5
1
0% 20% 40% 60% 80% 100%
27 
 
3.3.3. Additional Pharmacovigilance Activities 
The total number of additional pharmacovigilance activities was 47 in Japan and 123 
in Europe. Table 3-2 shows a comparison of the types and statuses of the additional 
pharmacovigilance activities in Japan and Europe. The most common additional 
pharmacovigilance activities in Europe were clinical trials, and the next were 
non-interventional studies. Although the non-interventional studies included drug 
utilization studies and cohort studies conducted using patient registries, there was only a 
single study for which it was clearly stated that a database was being used. The only 
additional pharmacovigilance activities in Japan were postmarketing surveillance 
studies and postmarketing clinical studies; there were 11 cases where the term of an 
ongoing clinical study was extended and the patients transitioned to a postmarketing 
clinical study. 
The number of additional pharmacovigilance activities per product was 5.0 (IQR: 
3.0-8.0) in Europe and 2.0 (IQR: 1.0-3.0) in Japan. In Europe, there were no products 
for which nonclinical studies, clinical trials, and non-interventional studies were all 
conducted: there were 12 products for which nonclinical studies were conducted, 15 
products for which clinical trials were conducted, and 14 products for which 
non-interventional studies were conducted. In Japan, postmarketing surveillance studies 
were conducted for all products, and there were 12 products for which postmarketing 
clinical studies were conducted. 
In Japan, there were 8 products for which the conduction of a postmarketing 
surveillance study in all patients (all-patient surveillance) was required as a condition of 
approval. When we examined the additional pharmacovigilance activities in Europe for 
these 8 products, we found that 23 nonclinical studies were conducted for 6 of these 
products, 27 clinical trials were conducted for 5 of these products (19 of which, 
covering all 5 products, were extensions of clinical trials), and 8 non-interventional 
studies were conducted for 6 products. 
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Table 3-2: Type and Status of additional pharmacovigilance activities (Part II)  [n (%)] 
 Planned /Planning Ongoing Completed Unknown Total 
EU      
Clinical trial  19 (29.7)  42 (65.6)   2 (3.1)   1 (1.6) 64 
Non-interventional study  23 (100.0)    0   0    0 23 
Non-clinical study 15 (45.5)   18 (54.5)   0   0 33 
Unknown   1 (33.3)  2 (66.7)   0   0  3 
Total 58 (47.2) 62 (50.4)   2 (1.6)   1 (0.8) 123 
Japan      
Postmarketing clinical study 8 (42.1) 11 (57.9) 0 0 19 
Postmarketing surveillance 
study 
28 (100.0) 0 0 0 28 
     Total 36 (76.6) 11 (23.4) 0 0 47 
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3.3.4. Associations between Safety Concerns and Additional Pharmacovigilance 
Activities 
In Europe, additional pharmacovigilance activities were conducted for 146 out of a 
total of 329 safety concerns (44.4%). In Japan, additional pharmacovigilance activities 
were conducted for 169 out of a total of 197 safety concerns (85.8%). Figure 3-3 shows 
the relationships between the categories of safety concerns and the presence or absence 
of additional pharmacovigilance activities. The proportion of identified risks for which 
additional pharmacovigilance activities were conducted was around 30% (23 of 85) in 
Europe, compared to around 90% (97 of 105) in Japan. 
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Figure 3-3: Safety concerns by types and how these are intended to be addressed: 
 a) Overall b) Identified risks 
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3.4. Part II: Discussion 
Comparison of the safety concerns and pharmacovigilance activities listed in the 
RMPs of products that have been approved in both Europe and Japan showed that the 
safety concerns were not necessarily the same in Europe and Japan, and that the total 
number of safety concerns in Europe was around 1.5 times as many as that in Japan. 
Although the number of identified risks was somewhat larger in Japan, the number of 
potential risks in Europe was twice as many as that in Japan, and the number of missing 
information in Europe was around 4 times as many as that in Japan. Although safety 
concerns that are classified as potential risks or missing information in the early 
postmarketing phase are occasionally reclassified as identified risks because safety 
concerns are revised based on the assessment of safety information obtained 
postmarketing, examination of the proportion of identified risks that were classified as 
identified risks only in Japan found no significant difference in this proportion between 
products that were put on the market at least half a year earlier in Europe and products 
that were put on the market in Europe and Japan at the same time (in each case, the 
proportion was around 30%). It therefore does not appear that the differences in safety 
concerns that exist between Japan and Europe may be attributed to differences in the 
timing of the market launch. 
Comparison of the safety concerns in Japan and Europe found that the proportion of 
SpAEs was higher in Japan. Furthermore, when context of use concerns were compared, 
excluding those that were listed only in Europe, it was found that the proportions of 
special age group and pregnancy/lactation concerns were higher in Europe, and the 
proportions of use in patients with specific comorbidities and use with concomitant 
medications concerns were higher in Japan. These findings suggested that while in 
Japan the focus is on specific adverse events (identified or potential risks) that have 
been elucidated to a certain extent by the time the product is approved, in Europe the 
focus is on collecting extensively the information that will be needed in the clinical 
setting. 
Comparison of the additional pharmacovigilance activities in Japan and Europe 
showed that, reflecting the regulatory systems of each region, in Europe a variety of 
activities such as nonclinical studies, clinical trials, and non-interventional studies were 
conducted, and in Japan postmarketing clinical studies and postmarketing surveillance 
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studies were conducted. When Japan was compared to Europe in the median number of 
additional pharmacovigilance activities per product, it was found that smaller number of 
additional pharmacovigilance activities per product was conducted in Japan. It was 
noteworthy that postmarketing surveillance studies were conducted for all products in 
Japan, demonstrating that Japan has more of a one-size-fits-all approach to 
pharmacovigilance activities. 
The European guidelines4) state that additional pharmacovigilance activities may or 
may not be needed depending on the extent to which the safety concerns have been 
elucidated. In Japan, the “Drug Product Risk Management Plan Guideline” 6) that was 
enacted in 2013 states that the necessity of conducting additional pharmacovigilance 
activities should be examined by referencing the ICH Harmonised Tripartite Guideline 
Pharmacovigilance Planning E2E5). In Europe, in fact, safety concerns for which 
additional pharmacovigilance activities were conducted accounted for around 40% of all 
safety concerns, and for around 30% of all known (identified) safety concerns. In Japan, 
in contrast, they accounted for 80% of all safety concerns, and 90% of known safety 
concerns. This clearly shows that, in Japan, additional pharmacovigilance activities are 
used for the collection of additional information about known adverse events.  
These findings show that although the objectives of the RMPs in Japan and Europe 
are the same, the approaches to pharmacovigilance that are used in the two regions are 
different, and whereas pharmacovigilance in Japan involves the conduction of largely 
standardized additional pharmacovigilance activities that are focused on obtaining 
information about known, specific adverse events, pharmacovigilance in Europe 
appears to be focused more on collecting a wide range of information that is needed in 
the clinical setting, and that in Europe routine pharmacovigilance activities and a variety 
of additional pharmacovigilance activities are used on more of a case-by-case basis. 
In light of these findings, we believe that it would be possible to collect safety 
information from a wide range of perspectives in Japan as well by researching the safety 
concerns that have been identified for an individual drug product through (1) identifying 
safety concerns by predicting how the drug product will be used in the clinical setting, 
irrespective of the risks of “specific adverse events,” (2) evaluating whether or not 
additional pharmacovigilance activities are really needed, and not conducting additional 
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pharmacovigilance activities for safety concerns for which additional information can 
be collected through only routine pharmacovigilance activities, and (3) positioning and 
conducting nonclinical studies and/or various types of observational studies as 
additional pharmacovigilance activities. Because the simultaneous global development 
of drug products is becoming increasingly common, research would also be needed on 
the international harmonization of safety concerns and pharmacovigilance activities, as 
well. 
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4. Overall Discussion 
The purpose of a risk management plan is to ensure safety of the drug product after 
the market launch by assessing the benefits and risks of the drug and implementing 
necessary safety measures based on these assessments. In Japan, the traditional 
framework of the re-examination system, the re-evaluation system, and the adverse drug 
reaction/infection reporting system, which are the foundation of Japan’s postmarketing 
safety measures, have been used to this end. The findings of our study show that, in 
Japan, additional pharmacovigilance activities are still dependent on postmarketing 
surveillance studies, as they were before the introduction of the RMP system. The 
results of our study also clearly show that the focus of additional pharmacovigilance 
activities in Japan is on collecting additional information about known adverse events. 
Because of the fact that the amount of safety information that has been obtained by 
the time of the market launch of a drug product is limited, and that there are differences 
in, for example, the use of concomitant medications in the clinical setting between the 
West and Japan, one important safety measure is the collection and assessment of more 
information on known adverse events. However, given that the number of new drugs 
that are being launched in Japan at nearly the same time as in the West is increasing and 
that the RMP system has been introduced, and given that the safety measures of risk 
management plans include not only the collection and assessment of safety information, 
but also the use of the assessed information to minimize the risks in the clinical setting, 
we believe that the implementation of risk minimization activities based on information 
about known adverse events that has already been obtained should be positioned as a 
more important safety measure than the collection of further information about these 
events. Furthermore, because medical institutions and companies do not have unlimited 
resources, we believe that the focus of collecting information by conducting additional 
pharmacovigilance activities needs to be on the detection of unknown risks and the 
specific conditions of use rather than on collecting additional information about known 
adverse events, and risk minimization activities need to be further improved by using 
combinations of additional pharmacovigilance activities based on these principles to 
more efficiently collect a wide range of information. 
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Both in the clinical setting and in companies, new drug RMPs are conducted in 
parallel with the RMPs of drug products that are already being used. The introduction of 
new approaches to additional pharmacovigilance activities may cause confusion, and we 
believe that a greater level of efficiency should be realized in stages. It has been 
reported that any meaningful safety information was obtained in around 40% of the 
additional pharmacovigilance activities (postmarketing surveillance studies) but the 
majority of safety actions taken based on the information were just the revisions to the 
frequency figures of the adverse drug reactions already listed in package inserts8). 
Therefore, we believe that a good first step towards improving pharmacovigilance in 
Japan would be to stop using stereotypical postmarketing surveillance studies to obtain 
information about safety concerns for which it appears that information could be 
collected by routine pharmacovigilance activities (spontaneous reporting of adverse 
drug reactions) alone. Instead, it would probably be more practical to use these 
resources to conduct additional pharmacovigilance activities that have as their central 
focus the detection of unknown risks and/or specific context of use safety concerns. 
In addition, although various medical databases that can be utilized for 
pharmacoepidemiology research have been prepared in recent years, and steps have 
been taken to utilize database research as one type of additional pharmacovigilance 
activity24), we found only a single study that clearly specified the use of a database as an 
additional pharmacovigilance activity in Europe in the present research. In the future, 
with the development of available databases, it is hoped that safety concerns for which 
the collection/assessment of safety information by such database research is suitable 
will be identified and higher quality safety measures are expected to be implemented. 
However, database research will not be applicable to all safety concerns, and the 
methods that are appropriate to the safety concerns of each individual product should be 
investigated. 
The limitations of our study include the fact that the data on the European RMPs 
were extracted from the EPARs at the time of approval and thus may differ from the 
actual RMPs. However, because it was based on the information provided in the review 
reports by the regulatory authorities, it is believed that there are no major differences. 
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Advances in the elucidation of disease thanks to scientific progress is resulting in the 
marketing of new drugs with a wide variety of mechanisms of action, and this has been 
accompanied by an increasing need for a wide variety of safety measures to be 
implemented in a timely fashion. Moreover, because the resources that are available to 
companies and medical practitioners for implementing postmarketing safety measures 
have certain limits, instead of allocating these resources in a one-size-fits-all manner to 
pharmacovigilance activities that focus on risks in general, including the risks that are 
already known, it will be necessary to use different combinations of a variety of 
pharmacovigilance activities, depending on the individual characteristics and safety 
concerns of each drug product, to focus on the detection and assessment of unknown 
risks and on the collection of information about specific context of use risks. 
 
  
37 
 
5. References 
 
1. Hirai Y, Kinoshita H, Kusama M, Yasuda K, Sugiyama Y, Ono S. Delays in new 
drug applications in Japan and industrial R&D strategies. Clin Pharmacol Ther 
2010; 87: 212–218. 
2. Tsuji K, Tsutani K. Approval of new biopharmaceuticals 1999-2006: comparison of 
the US, EU and Japan situations. Eur J Pharm Biopharm 2008; 68: 496–502. 
3. Yamada T, Kusama M, Hirai Y, Arnold F, Sugiyama Y, and Ono S. Analysis of 
Pharmaceutical Safety-Related Regulatory Actions in Japan: Do Tradeoffs Exist 
Between Safer Drugs and Launch Delay?. The Annals of Pharmacotherapy; 2010; 
44: 1976–1985. 
4. European Medicines Agency. Guideline on good pharmacovigilance practices 
(GVP). Module V—risk management systems. London: EMA; 2014. 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/201
2/06/WC500129134.pdf  Accessed 12 May 2016. 
5. International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH). ICH Harmonised Tripartite 
Guideline Pharmacovigilance Planning E2E. 2004. 
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy
/E2E/Step4/E2E_Guideline. pdf#search=’ICH?E2E. Accessed 12 May 2016. 
6. Ministry of Health, Labour and Welfare (MHLW) Pharmaceutical and Food Safety 
Bureau (PFSB) / Safety Division Notification No.0411 1, PFSB / Evaluation and 
Licensing Division Notification No.0411 2. Drug Product Risk Management Plan 
Guideline. April 11, 2012 
https://www.pmda.go.jp/files/000145482.pdf 
7. Iwasaki M，Watanabe T，Ujihara A，Narukawa M．The Current Status of 
Post-Marketing Surveillance in Japan and Future Challenges．Jpn J Clin Pharmacol 
Ther 2012; 43(5): 345-351. 
8. Narukawa M．Research on the Situation and Implications of the Post-marketing 
Surveillance Study in Japan – Consideration Based on a Questionnaire Survey．
Regulatory Science of Medical Products；2014；4(1)：11-19． 
9. Narukawa M．Research on the Situation and Implications of the Post- marketing 
All-case Surveillance Study in Japan – Consideration Based on a Questionnaire 
Survey. Regulatory Science of Medical Products；2014；4(3)：199-206． 
10. Watanabe T, Narukawa M．Questionnaire Survey of Post-Marketing Surveillance in 
Department Pharmacies．Japanese Journal of Pharmaceutical Health Care and 
38 
 
Sciences；2014；40(9)：517-514． 
11. Narukawa M．Actual State and Future Perspective of Post-marketing Surveillance 
Studies of Pharmaceuticals in Japan ． Pharmaceutical and Medical Device 
Regulatory Science；2014；45(11)：886-890． 
12. Kitajima Y, Shindo Y, Izawa K, Tanaka M. Summary of Risk Management Plans in 
PMDA Web Site by Using “RMP Summary Sheet” .  Pharmaceutical and Medical 
Device Regulatory Science; 2015; 46(7): 485-504 
13. Kokan A, Kubota K. A Review of Completed Activities of “The Task Force to 
Make an Ideal Pharmacovigilance Plan (PVP) in Japan” : Evaluation of the 
Published Pharmacovigilance Plan (PVP) by JSPE’s Check List and the Future 
Challenges．Jpn J Pharmacoepidemiol; 2014; 19(2): 115-122 
14. Vermeer NS, Duijnhoven RG, Straus SM, Mantel-Teeuwisse AK, Arlett PR, 
Egberts AC, Leufkens HG, De Bruin ML. Risk management plans as tool for 
proactive pharmacovigilance: a cohort study of newly approved drugs in Europe. 
Clin Pharmacol Ther. 2014; 96: 723–31. 
15. Raine J, Wise L, Blackburn S, Eichler HG, Breckenridge A. European perspective 
on risk management and drug safety. Clin Pharmacol Ther. 2011;89:650–4. 
16. Waller P. Getting to grips with the new European Union pharmacovigilance 
legislation. Pharmacoepidemiol Drug Saf. 2011; 20: 544–9. 
17. European Medicines Agency. One-year report on human medicines 
pharmacovigilance tasks of the European Medicines Agency. London: EMA; 2014. 
http://ec.europa.eu/health/files/pharmacovigilance/2014_ema_oneyear_pharmacov_
en.pdf. Accessed 12 May 2016. 
18. Zomerdijk IM, Sayed-Tabatabaei FA, Trifiro G, Blackburn SC, Sturkenboom MC, 
Straus SM. Risk minimization activities of centrally authorized products in the EU. 
Drug Saf. 2012; 35: 299–314. 
19. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Egberts TC, Blackburn S, Persson I, 
Leufkens HG. Evaluation of post-authorization safety studies in the first cohort of 
EU risk management plans at time of regulatory approval. Drug Saf. 2009;32:1175–
87. 
20. European Medicines Agency. European public assessment reports. London: EMA. 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_searc
h.jsp&mid=WC0b01ac058001d124. Accessed 2 Jan 2016. 
21. ClinicalTrials.gov. https://clinicaltrials.gov/. Accessed 29 Jan 2016. 
22. The European Network of Centres for Pharmacoepidemiology and 
Pharmacovigilance. Search Studies. http://www.encepp.eu/encepp/studySearch.htm. 
39 
 
Accessed 12 May 2016. 
23. Drug Product Risk Management Plan．Pharmaceuticals and Medical Devices 
Agency. 
http://www.pmda.go.jp/safety/info-services/drugs/items-information/rmp/0001.html. 
Accessed 16 Sept. 2016 
24. Koide D．Practical Use of Medical Database for Risk Management Plan (RMP). Jpn 
J Pharmacoepidemiol; 2014; 19(2): 133-141 
  
40 
 
6. Acknowledgement 
 
I would like to express my sincerest thanks to Professor Mamoru Narukawa for his 
invaluable guidance, numerous helpful suggestions, and kind words of encouragement. 
For this dissertation, I would like to thank the review committee members of my thesis: 
Dr. Yuji Yoshiyama, Dr. Hiroshi Homma, and Dr. Hajime Matsubara for their time, 
interest and helpful comments. I am also thankful to Mr. Masayuki Kaneko for his 
insightful advice and constant encouragement, and Ms. Akane Takayama for her support 
on numerous occasions. I am also grateful to Ms. Takako Nakata for all her help in 
preparing this dissertation, and also to all my supervisors and colleagues at 
Pharmaceuticals and Medical Devices Agency for their kind words of encouragement. 
Finally, I would like to thank my family. Without their support, I would not have been 
able to move to Tokyo and to find such a phenomenal research institute. 
  
41 
 
Appendix 1: List of 49 drug products in Part I 
 
Medicine Name Common name Therapeutic area EMA 
authorization 
date 
Krystexxa pegloticase Gout 08-Jan-13 
Amyvid florbetapir (18F) Radionuclide Imaging 14-Jan-13 
Tresiba insulin degludec Diabetes Mellitus 21-Jan-13 
Lyxumia  lixisenatide Diabetes Mellitus, Type 2 01-Feb-13 
Jetrea ocriplasmin Retinal Diseases 13-Mar-13 
Spedra avanafil Erectile Dysfunction 21-Jun-13 
Xtandi enzalutamide Prostatic Neoplasms 21-Jun-13 
Erivedge vismodegib Carcinoma, Basal Cell 12-Jul-13 
Imnovid pomalidomide Multiple Myeloma 05-Aug-13 
Tafinlar dabrafenib Melanoma 26-Aug-13 
Vipidia alogliptin benzoate Diabetes Mellitus, Type 2 19-Sep-13 
Giotrif Afatinib Carcinoma, Non-Small-Cell Lung 25-Sep-13 
NovoEight turoctocog alfa Hemophilia A 13-Nov-13 
Xofigo radium Ra223 
dichloride 
Prostatic Neoplasms 13-Nov-13 
Invokana canagliflozin Diabetes Mellitus, Type 2 15-Nov-13 
Kadcyla trastuzumab emtansine Breast Neoplasms 15-Nov-13 
Brintellix vortioxetine Depressive Disorder, Major 18-Dec-13 
Tivicay dolutegravir HIV Infections 16-Jan-14 
Sovaldi sofosbuvir Hepatitis C, Chronic 16-Jan-14 
Tecfidera dimethyl fumarate Multiple Sclerosis 30-Jan-14 
Neuraceq florbetaben(18F) Radionuclide Imaging 
Alzheimer Disease 
20-Feb-14 
Sirturo bedaquiline Tuberculosis, Multidrug-Resistant 05-Mar-14 
Eperzan albiglutide Diabetes Mellitus, Type 2 21-Mar-14 
Cometriq cabozantinib Thyroid Neoplasms 21-Mar-14 
Latuda lurasidone Schizophrenia 21-Mar-14 
Adempas riociguat Hypertension, Pulmonary 27-Mar-14 
Vimizim elosulfase alfa Mucopolysaccharidosis IV 28-Apr-14 
Deltyba delamanid Tuberculosis, Multidrug-Resistant 28-Apr-14 
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Incruse umeclidinium bromide Pulmonary Disease, Chronic 
Obstructive 
28-Apr-14 
Olysio simeprevir Hepatitis C, Chronic 14-May-14 
Jardiance empagliflozin Diabetes Mellitus, Type 2 22-May-14 
Entyvio vedolizumab Colitis, Ulcerative 
Crohn Disease 
22-May-14 
Sylvant siltuximab Giant Lymph Node Hyperplasia 22-May-14 
Mekinist trametinib Melanoma 30-Jun-14 
Plegridy peginterferon beta-1a Multiple Sclerosis 18-Jul-14 
Gazyvaro obinutuzumab Leukemia, Lymphocytic, Chronic, 
B-Cell 
23-Jul-14 
Nuwiq simoctocog alfa 
(rFVIII) 
Hemophilia A 24-Jul-14 
Translarna ataluren Muscular Dystrophy, Duchenne 31-Jul-14 
Daklinza daclatasvir Hepatitis C, Chronic 22-Aug-14 
Vizamyl flutemetamol (18F) Radionuclide Imaging 
Alzheimer Disease 
22-Aug-14 
Zydelig idelalisib Lymphoma, Non-Hodgkin 
Leukemia, Lymphocytic, Chronic, 
B-Cell 
18-Sep-14 
Imbruvica ibrutinib Lymphoma, Mantle-Cell 21-Oct-14 
Lymphoseek tilmanocept Radionuclide Imaging 19-Nov-14 
Trulicity dulaglutide Diabetes Mellitus, Type 2 21-Nov-14 
Vargatef nintedanib Carcinoma, Non-Small-Cell Lung 21-Nov-14 
Moventig naloxegol Constipation 08-Dec-14 
Lynparza olaparib Ovarian Neoplasms  16-Dec-14 
Cyramza ramucirumab Stomach Neoplasms 19-Dec-14 
Scenesse afamelanotide Protoporphyria, Erythropoietic 22-Dec-14 
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Appendix 2: Safety concerns of 20 drug products in Part Ⅱ 
  Europe Japan 
  Safety concerns authorization 
date 
Safety concerns authorization 
date 
alogliptin identified risk Hypersensitivity reactions, Pancreatitis 2013/9/19 Rhabdomyolysis, Hepatotoxicity・
Jaundice, Interstitial pneumonia, Acute 
pancreatitis, Angioedemas, Intestinal 
obstruction, Hypoglycaemia , Stevens 
Johnson syndrome / Erythema 
multiforme 
2010/4/16 
potential risk Gastrointestinal disorders, Hepatotoxicity, 
Infections, Peripheral necrotic skin lesions 
 Malignant tumor, Infections  
missing 
information 
Children and adolescents, Malignancies, 
Patients with concurrent CV disease, 
Patients with severe hepatic impairment, 
Patients with severe renal impairment or 
End-Stage Renal disease (ESRD) requiring 
dialysis, Pregnant and/or breastfeeding 
women 
 Patients with severe hepatic impairment 
Use in very elderly patients, Patients 
with concurrent CV disease, Patients 
with severe renal impairment 
 
canagliflozin identified risk Balanitis or balanoposthitis, 
Hypoglycaemia in combination with 
insulin or glucose-independent insulin 
secretagogues, Urinary tract infections, 
2013/11/15 Ketoacidosis / Blood ketone body 
increased, Genital infection, Frequency 
of urination and polyuria, Volume 
depletion, Hypoglycaemia , Urinary tract 
2014/7/4 
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Volume depletion, Vulvovaginal 
candidiasis 
infections 
potential risk Hypoglycaemia in the absence of insulin 
or glucose-independent, Insulin 
secretagogues, Off-label use for weight 
loss, Clinical consequences of increased 
haematocrit, Bone fractures, Renal 
impairment/Renal failure, Photosensitivity 
 Malignant tumor, Fractures, Renal 
impairment, Weight loss 
 
missing 
information 
Long-term cardiovascular safety in 
patients, Use in nursing mothers, Use in 
paediatric patients between 10 and 18 
years of age, Use in patients with 
congestive heart failure defined as NYHA 
class IV, Use in patients with severe 
hepatic impairment, Use in patients with 
severe renal impairment 
(eGFR<30mG/min/1.73m2), Use in 
pregnancy, Use in very elderly patients (≥ 
85 years) 
 Hypoglycaemia in the absence of insulin 
or glucose-independent, Use in patients 
with severe hepatic impairment, Use in 
very elderly patients, Patients with 
concurrent CV disease, Use in patients 
with renal impairment 
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dabrafenib identified risk Cutaneous SCC (cuSCC; cutaneous 
squamous cell carcinomas), 
Hypersensitivity, New primary melanoma, 
Non-cutaneous secondary/recurrent 
malignancies, Palmar-Plantar 
Erythrodysesthesia Syndrome (PPES), 
Pancreatitis, Pre-renal and Intrinsic Renal 
failure, Pyrexia, Uveitis 
2013/8/26 Hepatic impairment, Eye disorders, 
Cardiac impairment, Pyrexia, Cutaneous 
SCC (cuSCC; cutaneous squamous cell 
carcinomas), Non-cutaneous 
secondary/recurrent malignancies 
2016/3/28 
potential risk Drug-drug interactions, Hyperglycaemia, 
Increased risk for Grade 3 or 4 AEs, SAEs 
or dose adjustments in elderly population 
(≥65 years), Non-specific cardiac toxicity, 
Off-label use in resectable/resected 
melanoma (adjuvant treatment), 
non-melanoma tumours harbouring a 
BRAFV600-mutation, in combination with 
other anti-cancer agents, or when 
non-validated tests are used, Paediatric 
effects, Photosensitivity, Potential for QT 
Prolongation, Testicular Toxicity 
 Potential for QT Prolongation, Deep 
vein thrombosis / Pulmonary embolism, 
Testicular Toxicity, Cerebrovascular 
disorder, Pancreatitis 
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missing 
information 
Developmental toxicity and risks in 
breast-feeding, Long-term treatment, Rare 
adverse reactions, Risks in patients with 
ECOG 2-4, Safety in patients with 
moderate to severe hepatic impairment, 
Safety in patients with severe renal 
impairment, Use in Non-White population, 
Use in patients with baseline QTc ≥480 
msec; history of acute coronary syndrome 
(including unstable angina), coronary 
angioplasty, stenting or cardiac 
arrhythmias (except sinus arrhythmia) 
within the past 24 weeks; and abnormal 
cardiac valve morphology (moderately 
abnormal or worse), Use in patients with 
reduce cardiac function or symptomatic 
NYHA Class II, III, or IV heart failure 
(NYHA functional classification system) 
 Safety in patients with hepatic 
impairment 
 
daclatasvir 
dihydrochloride 
identified risk - 2014/8/22 Hepatitis B reactivation, Hepatic 
impairment, Interstitial pneumonia, 
Thrombocytopenias, Erythema 
multiforme 
2014/7/4 
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potential risk CYP3A inhibitors and inducers; P-gp i- 
inhibitors, inducers, and substrates; 
OATP1B1, OATP1B3, and BCRP 
substrates, Development of Drug 
Resistance, Embryo-fetal Development 
Toxicity, Hematologic Toxicity, Hepatic 
Toxicity 
 Hematologic Toxicity  
missing 
information 
Children and Adolescents (<18 years of 
age), HBV/HCV, Hepatic Impairment and 
Decompensated Liver Disease, HIV/HCV, 
Liver Transplant, Pregnancy and Lactation, 
Subjects aged > 65 years, Subjects 
co-medicated with interacting agents dosed 
at either 30 mg/day or 90 mg/day, Subjects 
of African origin; 
 -  
dolutegravir identified risk Drug Interactions, Drug resistance, 
Hepatobiliary disorders, Hypersensitivity 
reactions 
2014/1/16 Hepatic impairment, Increased 
occurrence of IRIS, Hypersensitivity 
reactions 
2014/3/24 
potential risk GI Intolerance and erosions, Increased 
occurrence of IRIS, Lipase elevations 
(Grade 3 and 4), Muscoskeletal events/ 
elevated CPK elevations, Phototoxicity, 
Psychiatric disorders, Renal disorders, 
 Muscoskeletal events, Drug Interactions  
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Serious rash (DAIDS Grade 3 or 4) 
missing 
information 
Affinity of DTG to melanocortin receptors, 
Long term safety data, Use in patients with 
severe hepatic impairment, Use in 
pregnancy/ breastfeeding, Use in the 
elderly 
 Long term safety data, Use in Japanese 
patients with HIV, Use in pregnancy/ 
breastfeeding 
 
dulaglutide identified risk Acute pancreatitis, Gastrointestinal events, 
Hypoglycaemia 
2014/11/21 Gastrointestinal events, Injection site 
reactions, Hypoglycaemia  
 
2015/7/3 
potential risk Cardiovascular effects, Hypersensitivity, 
Medication errors (more than one injection 
per week), Pancreatic malignancy, Thyroid 
C-cell tumours 
 Hyperglycaemia (Use in patients treated 
insulin), Hypersensitivity reactions, 
Acute pancreatitis, Thyroid C-cell 
tumours, Cardiovascular disorder, 
Intestinal obstruction, Pancreatic 
malignancy、Intestinal obstruction 
 
 
missing 
information 
Confirmation of memory deficits in 
directly dosed immature rats, Use in 
children and adolescents <18 years of age, 
Use in patients aged ≥75 years, Use in 
patients with congestive heart failure, Use 
 Concomitant use with insulin, Use in 
patients with hepatic impairment, Use in 
elderly patients , Use in patients with 
renal failure 
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in patients with hepatic impairment, Use in 
patients with severe renal failure, Use in 
pregnant and/or breastfeeding women 
empagliflozin identified risk Genital infection, Hypoglycaemia (with 
insulin and/or sulphonylurea), Urinary 
tract infection, Volume depletion 
2014/5/22 Hypoglycaemia, Ketoacidosis / Blood 
ketone body increased, Genital infection, 
Frequency of urination and polyuria, 
Volume depletion, Urinary tract infection 
2014/12/26 
potential risk Bone fracture, Liver injury, Off-label use 
(e.g. for weight loss in non-T2DM 
patients), Renal impairment, Urinary tract 
carcinogenicity 
 Malignant tumor, Fractures, Renal 
impairment, Weight loss 
 
missing 
information 
Clinical impact of dyslipidaemia, 
Concomitant use with GLP-1 analogues, 
Elderly patients, Long-term safety 
(particularly cardiovascular), Missing 
long-term safety information on 
melanoma, Paediatric patients, 
Pregnancy/breast-feeding, Use in patients 
with severe hepatic impairment 
 Concomitant use with GLP-1 analogues 
Use in patients with hepatic impairment, 
Use in elderly patients , Patients with 
concurrent CV disease, Use in patients 
with renal impairment 
 
enzalutamide identified risk Falls, Hallucination, Hypertension, 
Interactions with medicinal products that 
are substrates of CYP3A4, CYP2C9 or 
CYP2C19, Interactions with strong 
2013/6/21 Interactions with medicinal products that 
are substrates of CYP2C8, 
Thrombocytopenias, Seizures 
2014/3/24 
50 
 
inhibitors or inducers of CYP2C8, 
Neutrophil count decreased, 
Non-pathologic fracture, Seizures 
potential risk Cognitive/memory impairment 
 
 Neuropsychiatric disorders  
missing 
information 
Patients of non-White race, Patients with 
brain metastases or with baseline factors 
predisposing for seizure, Patients with 
ECOG PS ≥ 2, Patients with metastatic 
castration-resistant prostate cancer 
previously treated with abiraterone acetate, 
Patients with moderate or severe hepatic 
impairment, Patients with severe 
cardiovascular disease, Patients with 
severe renal impairment, 
Reproduction/fertility 
 -  
ibrutinib identified risk Haemorrhage, Leukostasis 2014/10/21 Interactions with CYP3A inhibitors, 
Hypersensitivity, Infections, Use in 
patients with hepatic impairment, 
Hepatic impairment, Interstitial 
pneumonia, Eye disorders, Marrow 
depression, Tumour lysis syndrome, 
2016/3/28 
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Haemorrhage, Secondary malignancy, 
Cardiac arrhythmia 
potential risk Anaemia, Cardiac arrhythmia, Drug-drug 
interaction, Eye disorders, 
Hypersensitivity, Hypertension, Infections, 
Neutropenia, Other malignancies, Renal 
failure, Severe GI disorders, 
Teratogenicity, Thrombocytopenia, 
Tumour lysis syndrome 
 
 Leukostasis, Stevens Johnson syndrome  
missing 
information 
Long term use (>2 years), Off-label use in 
paediatric patients, Use during 
breastfeeding, Use in patients with severe 
cardiac disease, Use in patients with severe 
hepatic impairment, Use in patients with 
severe renal impairment 
 -  
insulin degludec identified risk Hypoglycaemia, Immunogenicity-related 
events (allergic reactions) 
2013/1/21 Allergic reactions, Injection site 
reactions, Hypoglycaemia  
 
2012/9/28 
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potential risk Immunological events – formation of 
neutralising insulin antibodies, Medication 
errors due to mix-up between basal and 
bolus insulin, Medication errors due to 
mix-up between the different 
concentrations of Tresiba 
 Immunological events – formation of 
neutralising insulin antibodies, 
Medication errors due to mix-up 
between basal and bolus insulin 
 
missing 
information 
Children and adolescents < 18 years, 
Co-administration with GLP-1, Elderly 
patients (>75 years) with T1DM, Hepatic 
impairment, Moderate and severe renal 
impairment, Pregnant and lactating women 
 Children < 5 years, Hepatic impairment, 
Elderly patients, Patients with 
concurrent CV disease, Renal 
impairment, Pregnant and lactating 
women 
 
nintedanib identified risk Bleeding, Diarrhoea, Hypertension, Liver 
enzyme elevations and 
hyperbilirubinaemia, Neutropenia, 
Perforation (gastro-intestinal and 
non-gastro-intestinal), Sepsis, Venous 
thromboembolism 
2014/11/21 Diarrhoea / Nausea, Hepatic impairment, 
Thrombocytopenias, Thromboembolism, 
Gastrointestinal perforation 
2015/7/3 
potential risk Arterial thromboembolism, Cardiac 
failure, Hepatic failure, QT prolongation, 
Treatment in pregnant women and 
teratogenicity 
 Osteonecrosis of jaw, Interstitial 
pneumonia, Severe skin reactions, 
Haemorrhage, Impaired wound healing, 
Patients with severe hepatic impairment 
(Child–Pugh B or C) 
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missing 
information 
In vitro inhibitory potential on OAT1 and 
OAT3, Treatment of breastfeeding women, 
Treatment of patients weighing < 50 kg, 
Treatment of patients with healing wounds, 
Treatment of patients with hepatic 
impairment, Treatment of patients with 
renal impairment, Treatment of 
subpopulations with co-morbid CNS 
conditions such as dementia, depression, 
brain metastasis, or with co-morbid 
conditions such as arthritis and 
osteoporosis 
 -  
pomalidomide identified risk Infection, Neutropenia, Peripheral 
neuropathy, Somnolence, Teratogenicity, 
Thrombocytopenia and bleeding, 
Thromboembolic events, Tumour lysis 
syndrome 
2013/8/5 Hypersensitivity reactions, Infection, 
Hepatic impairment・Jaundice, 
Interstitial pneumonia, Acute kidney 
failure, Somnolence・Sensorium 
decreased・Confusion・Fatigue・
Dizziness, Thromboembolism, Marrow 
depression, Teratogenicity, Tumour lysis 
syndrome, Cardiac failure, Cardiac 
arrhythmia, Peripheral neuropathies 
2015/3/26 
potential risk Cardiac arrhythmia, Cardiac failure, 
Off-label use, QT interactions 
 Secondary malignancy  
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(prolongation), Renal failure, Second 
primary malignancies, Second primary 
malignancies, Severe skin reactions, 
Thyroid disorders 
missing 
information 
Interaction with oral contraceptives, 
Interactions with drugs affecting and 
metabolised by cytochrome P450 1A2, 
3A4/5 and P-glycoprotein, Paediatric use, 
Use during breast-feeding, Use in patients 
of different racial origin, Use in patients 
with hepatic impairment, Use in patients 
with renal impairment 
 Use in patients with hepatic impairment, 
Use in patients with renal impairment 
 
radium Ra223 
dichloride 
identified risk Bone marrow toxicity leading to reduction 
in formed elements in blood 
2013/11/13 Marrow depression 2016/3/28 
potential risk Bone sarcoma, Late bone marrow toxicity, 
Myelodysplastic syndrome/Acute myeloid 
leukaemia (MDS/AML), Off-label 
administration of repeated courses of 
treatment, or other administration of doses 
in excess of those recommended in the 
product information, Off-label use in 
women and children, Osteonecrosis of the 
jaw, Secondary malignancies (other than 
 Secondary malignancy  
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MDS/AML and bone sarcoma) 
missing 
information 
Clinical safety in non-white ethnic groups, 
Clinical safety in patients receiving 
calcium supplementation, phosphates or 
vitamin D, Clinical safety in patients 
receiving chemotherapy, Clinical safety in 
patients receiving external beam radiation 
therapy to bone or prostate, Clinical safety 
in patients with inflammatory bowel 
disease, Developmental toxicity due to 
off-label use in children, Reproductive 
toxicity due to off-label use in women, 
Reproductive toxicity in men with 
metastatic CRPC 
 -  
ramucirumab identified risk Arterial thromboembolic events, 
Bleeding/Haemorrhagic events, 
Congestive heart failure, Fistula formation, 
GI perforation, Hypertension, Impaired 
2014/12/19 Infusion-related reaction, Ischemic heart 
disease, Reversible posterior 
leukoencephalopathy syndrome, 
Neutropenia, Hypertension, 
2015/3/26 
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wound healing, Infusion-related reaction, 
Liver failure / liver injury, Neutropenia, 
Proteinuria 
Haemorrhage, Gastrointestinal 
perforation, Embolism venous, Impaired 
wound healing, Proteinuria / Nephrotic 
syndrome, Embolism arterial, Fistula 
potential risk Abdominal pain, Anaemia, Reproductive 
and developmental toxicity, Reversible 
Posterior Leukoencephalopathy Syndrome, 
VTE (Venous thromboembolic event) 
 Liver failure, Interstitial pneumonia  
missing 
information 
Carcinogenicity, Genotoxicity  -  
recombinant 
human 
n-acetylgalactos
amine-6-sulfatas
e (rhgalns) 
(elosulfase alfa) 
identified risk Infusion reactions (including anaphylaxis 
and severe allergic reactions) 
2014/4/28 Infusion reactions (including 
anaphylaxis and severe allergic 
reactions) 
 
2014/12/26 
potential risk Immunogenicity, Medication Errors, 
Spinal/Cervical Cord Compression 
(including laxity and unmasking 
myelopathic symptoms) 
 
 Immunogenicity  
missing 
information 
Limitations of the safety database, Safety 
in patients with hepatic impairments, 
safety in patients with renal impairments, 
safety in patients with cardiac 
 Use in children  
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impairments, and safety in pregnancy and 
lactation 
riociguat identified risk Hypotension, Serious 
haemoptysis/pulmonary Haemorrhage, 
Upper gastrointestinal motility disorders, 
Worsening of pulmonary venous occlusive 
disease 
2014/3/27 Upper gastrointestinal motility disorders, 
Hypotension, Worsening of pulmonary 
venous occlusive disease 
2014/1/17 
potential risk Bleeding, Bone changes and fractures, 
Concomitant smoking (induction of 
CYP1A1), Embryo–foetal toxicity, 
Medication error, Off-label use in patients 
aged < 18 years, Renal failure, Treatment 
of patients with pre-existing atrial 
fibrillation 
 Concomitant smoking, Haemoptysis・
Pulmonary haemorrhage, Concomitant 
use with CYP1A1 inhibitors 
 
missing 
information 
Long-term safety in clinical practice, 
Patients aged < 18 years, Patients with 
chronic thromboembolic pulmonary 
hypertension (CTEPH) or pulmonary 
arterial hypertension (PAH) in World 
Health Organisation (WHO) functional 
class IV, Patients with creatinine clearance 
< 30 mL/min or on dialysis, Patients with 
 Patients with hepatic impairment, 
Patients with renal impairment, 
Long-term safety in clinical practice, 
Patients with systolic blood pressure < 
95 mmHg at baseline, Concomitant use 
with CYP3A inhibitors, CYP1A1 
inhibitors or P-gp/BCRP inhibitors  
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severe hepatic impairment (Child–Pugh 
C), Patients with systolic blood pressure < 
95 mmHg at baseline, Patients with 
uncontrolled hypertension, Pregnancy and 
lactation 
simeprevir identified risk Photosensitivity conditions, Rash 2014/5/14 Hepatitis B reactivation, Hepatic 
impairment, Photosensitivity conditions, 
Hyperbilirubinaemia, Cerebral 
haemorrhage, Sepsis  
2013/9/27 
potential risk Development of drug resistance  Erythema multiforme, Neutropenias, 
Anaemia 
 
missing 
information 
Drug-drug interactions, OLYSIO + 
medicinal products other than 
peginterferon alfa and ribavirin, Use in 
children and adolescents (≥3 to <18 years), 
Use in elderly patients (>65 years), Use in 
HCV/HBV co-infection, Use in organ 
transplant patients, Use in patients 
previously treated with a HCV protease 
inhibitor or other direct-acting antivirals, 
Use in patients with GFR <30 
 -  
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mL/min/1.73 m2, Use in patients with 
moderate or severe hepatic impairment or 
decompensated liver disease, Use in 
pregnant or breast-feeding women 
sofosbuvir identified risk - 2014/1/16 Hepatitis B reactivation, Hypertension, 
Cerebrovascular disorder 
2015/3/26 
potential risk Drug-drug interaction with potent 
intestinal Pgp inducers 
 Safety in patients with severe renal 
impairment or end-stage renal disease, 
Anaemia 
 
missing 
information 
Safety in children, Safety in patients with 
severe renal impairment or end-stage renal 
disease, Safety in pregnant or 
breastfeeding women 
 -  
trametinib identified risk Diarrhoea, Haemorrhagic events, Hepatic 
events (AST, ALT, increased), 
Hypersensitivity, Hypertension, Left 
ventricular systolic dysfunction (e.g., 
LVEF decreased and left ventricular 
dysfunction), Ocular events (e.g., retinal 
vein occlusion, retinal pigment epithelial 
2014/6/30 Rhabdomyolysis, Hepatic impairment, 
Eye disorders, Cardiac impairment, 
Pyrexia 
2016/3/28 
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detachment), Oedema events (e.g. oedema 
peripheral), Pneumonitis, 
Rhabdomyolysis, Skin toxicities (e.g., 
rash, dermatitis acneiform,) 
potential risk Developmental toxicity, Hepatic failure, 
Impaired female fertility, Off-label use: in 
resectable/resected melanoma (adjuvant 
treatment), in nonmelanoma tumours 
harbouring a BRAF V600- mutation, 
melanoma tumours negative for BRAF 
V600-mutation, in patients with tumour 
progression during prior treatment with 
BRAF inhibitor therapy, use in 
combination with other anti-cancer agents, 
or when non-validated tests are used 
 Interstitial pneumonia, Impaired female 
fertility, Deep vein thrombosis・
Pulmonary embolism , Renal 
impairment , Cerebrovascular disorder, 
Developmental toxicity 
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missing 
information 
Drug-drug interactions (i.e., Enzymes 
responsible for the hydrolytic cleavage of 
trametinib, Potential for saturation of P-gp 
and BCRP, Whether trametinib is a 
substrate of OATP1B1 and OATP1B3 and 
whether trametinib is an inhibitor of 
OCT2, OAT1, or OAT3), Long-term 
treatment (>12 months), Pregnancy and 
risks in breast-feeding, Risks in patients 
with ECOG 2-4, Safety in elderly (>65 
years) patients, Safety in patients with 
baseline QTc ≥480 msec QT prolongation, 
recent (within 6 months) acute coronary 
syndrome including unstable angina, 
coronary angioplasty , stenting or cardiac 
arrhythmias (except sinus arrhythmia), 
treatment refractory hypertension (blood 
pressure of systolic> 140 mmHg and/or 
diastolic > 90 mm Hg which cannot be 
controlled by anti-hypertensive therapy), 
Safety in patients with history of 
pneumonitis or interstitial lung disease, 
Safety in patients with history of retinal 
 Safety in patients with hepatic 
impairment 
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vein occlusion or central serous 
retinopathy (reclassified as Retinal 
Pigment Epithelial Detachment, RPED), 
Safety in patients with moderate to severe 
hepatic impairment, Safety in patients with 
severe renal impairment, Use in 
Non-White population, Use in paediatric 
population (children less than 18 years), 
Use in patients with reduced cardiac 
function or symptomatic Class II, III, or IV 
heart failure (NYHA functional 
classification system) 
umeclidinium identified risk - 2014/4/28 Cardiovascular disorder 2015/3/26 
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bromide potential risk Bladder outflow obstruction and urinary 
retention, Cardio and Cerebrovascular 
Disorders, Lower Respiratory Tract 
Infection (incl. pneumonia), Narrow angle 
glaucoma, Paradoxical brochospasm 
(which may be life threatening) 
 -  
missing 
information 
Interaction with other medicines, Safety in 
long-term use, Safety in pregnancy and 
lactation, Safety in severe hepatic 
impairment 
 -  
 
